Protective effects of astragaloside IV on IL‑8‑treated diaphragmatic muscle cells

Wang,Li; Gu,Wei; Shi,Ying; Chen,Yubao; Tan,Yan

doi:10.3892/etm.2018.6940

Protective effects of astragaloside IV on IL‑8‑treated diaphragmatic muscle cells

Authors:
- Li Wang
- Wei Gu
- Ying Shi
- Yubao Chen
- Yan Tan
View Affiliations

Affiliations: Department of Respiratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China
Published online on: November 8, 2018 https://doi.org/10.3892/etm.2018.6940
Pages: 519-524

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The diaphragmatic fatigue that results from airflow obstruction is associated with the severe morbidity of patients with chronic obstructive pulmonary disease. Astragaloside IV (AS‑IV) has antioxidant, anti‑apoptotic and anti‑inflammatory activities in various cell types. The present study aimed to evaluate the protective effects of AS‑IV in diaphragmatic muscle cells. Diaphragmatic muscle cells extracted from neonatal rats were treated with a series of AS‑IV concentrations (5, 10 or 20 mg/l) and the AKT inhibitor GSK690693 in the presence of interleukin‑8 (IL‑8). Cell proliferation and AKT phosphorylation were measured using Cell Counting Kit‑8 and western blot assays, respectively. Cell apoptosis and reactive oxygen species (ROS) production were evaluated using flow cytometric analysis. Caspase activity and concentrations of proinflammatory factors (tumor necrosis factor‑α, IL‑6 and IL‑8) were assessed using a caspase colorimetric assay and ELISA, respectively. IL‑8 treatment resulted in decreased rates of cell proliferation and increased rates of AKT phosphorylation, cell apoptosis, caspase 3/9 activity, ROS production and proinflammatory factor production. AS‑IV and GSK690693 treatment reversed the effects of IL‑8. The effects of AS‑IV were dose‑dependent. The present results suggested that AS‑IV is a candidate for the treatment of diaphragmatic fatigue due to its antioxidant, anti‑apoptotic and anti‑inflammatory activity.

View Figures

View References

1	Ni Y, Shi G, Yu Y, Hao J, Chen T and Song H: Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: A systemic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 28:1465–1475. 2015. View Article : Google Scholar
2	Smith-Blair N: Mechanisms of diaphragm fatigue. AACN Clin Issues. 13:307–319. 2002. View Article : Google Scholar : PubMed/NCBI
3	Demedts IK, Demoor T, Bracke KR, Joos GF and Brusselle GG: Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res. 7:532006. View Article : Google Scholar : PubMed/NCBI
4	Kirkham PA and Barnes PJ: Oxidative stress in COPD. Chest. 144:266–273. 2013. View Article : Google Scholar : PubMed/NCBI
5	Kyroussis D, Polkey MI, Keilty SE, Mills GH, Hamnegard CH, Moxham J and Green M: Exhaustive exercise slows inspiratory muscle relaxation rate in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 153:787–793. 1996. View Article : Google Scholar : PubMed/NCBI
6	Mador MJ, Kufel TJ, Pineda LA and Sharma GK: Diaphragmatic fatigue and high-intensity exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 161:118–123. 2000. View Article : Google Scholar : PubMed/NCBI
7	Reid MB: Free radicals and muscle fatigue: Of ROS, canaries, and the IOC. Free Radic Biol Med. 44:169–179. 2008. View Article : Google Scholar : PubMed/NCBI
8	Keatings VM, Collins PD, Scott DM and Barnes PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 153:530–534. 1996. View Article : Google Scholar : PubMed/NCBI
9	Bozinovski S, Vlahos R, Hansen M, Liu K and Anderson GP: Akt in the pathogenesis of COPD. Int J Chron Obstruct Pulmon Dis. 1:31–38. 2006.PubMed/NCBI
10	Cao LL, Li WZ, Si XL, Sun L and Li WP: Protective effect and mechanism of astragaloside IV on oxidative stress injury of mesangial cells. Zhongguo Zhong Yao Za Zhi. 38:725–730. 2013.(In Chinese). PubMed/NCBI
11	Ji KT, Tang JF and Chai JD: Effect of astragaloside against the oxidative damage on endothelial cells. Zhongguo Zhong Xi Yi Jie He Za Zhi. 31:807–810. 2011.(In Chinese). PubMed/NCBI
12	Sun L, Li W, Li W, Xiong L, Li G and Ma R: Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NFkappaB pathway under high glucose conditions. Int J Mol Med. 34:167–176. 2014. View Article : Google Scholar : PubMed/NCBI
13	Zhang A, Zheng Y, Que Z, Zhang L, Lin S, Le V, Liu J and Tian J: Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO. J Cancer Res Clin Oncol. 140:1883–1890. 2014. View Article : Google Scholar : PubMed/NCBI
14	Qiu YY, Zhu JX, Bian T, Gao F, Qian XF, Du Q, Yuan MY, Sun H, Shi LZ and Yu MH: Protective effects of astragaloside IV against ovalbumin-induced lung inflammation are regulated/mediated by T-bet/GATA-3. Pharmacology. 94:51–59. 2014. View Article : Google Scholar : PubMed/NCBI
15	Shang L, Qu Z, Sun L, Wang Y, Liu F, Wang S, Gao H and Jiang F: Astragaloside IV inhibits adenovirus replication and apoptosis in A549 cells in vitro. J Pharm Pharmacol. 63:688–694. 2011. View Article : Google Scholar : PubMed/NCBI
16	Sun J, Chen XL, Zheng JY, Zhou JW and Ma ZL: Astragaloside IV protects new born rats from anesthesia-induced apoptosis in the developing brain. Exp Ther Med. 12:1829–1835. 2016. View Article : Google Scholar : PubMed/NCBI
17	Hu JY, Han J, Chu ZG, Song HP, Zhang DX, Zhang Q and Huang YS: Astragaloside IV attenuates hypoxia-induced cardiomyocyte damage in rats by upregulating superoxide dismutase-1 levels. Clin Exp Pharmacol Physiol. 36:351–357. 2009. View Article : Google Scholar : PubMed/NCBI
18	Zhang ZG, Wu L, Wang JL, Yang JD, Zhang J, Zhang J, Li LH, Xia Y, Yao LB, Qin HZ and Gao GD: Astragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production. Mol Cell Biochem. 364:209–216. 2012. View Article : Google Scholar : PubMed/NCBI
19	Zhang L, Liu Q, Lu L, Zhao X, Gao X and Wang Y: Astragaloside IV stimulates angiogenesis and increases hypoxia-inducible factor-1α accumulation via phosphatidylinositol 3-kinase/Akt pathway. J Pharmacol Exp Ther. 338:485–491. 2011. View Article : Google Scholar : PubMed/NCBI
20	Jia Y, Zuo D, Li Z, Liu H, Dai Z, Cai J, Pang L and Wu Y: Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway. Chem Pharm Bull (Tokyo). 62:45–53. 2014. View Article : Google Scholar : PubMed/NCBI
21	Demoule A, Divangahi M, Danialou G, Gvozdic D, Larkin G, Bao W and Petrof BJ: Expression and regulation of CC class chemokines in the dystrophic (mdx) diaphragm. Am J Respir Cell Mol Biol. 33:178–185. 2005. View Article : Google Scholar : PubMed/NCBI
22	Elmore S: Apoptosis: A review of programmed cell death. Toxicologic pathology. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI